Another Partner for Halozyme-Pfizer Deal Could Total $515M

Halozyme Therapeutics Inc. added another feather in its partnership cap with Pfizer Inc. inking a worldwide collaboration and license agreement to develop and commercialize products that combine their recombinant human hyaluronidase enzyme (rHuPH20) with biologics directed to up to six unnamed targets.